Scope and Claims Analysis of US Patent 10,272,046 (Compound 1 Solid-Dispersion Unit-Dose Formulation) and the U.S. Patent Landscape
US Patent 10,272,046 claims a narrow, unit-dose solid-dispersion tablet/mini-tablet formulation of a specific amorphous drug (“Compound 1”) with defined excipient ratios and a strict placement constraint for sodium lauryl sulfate (SLS). The estate’s enforceable core is composition and method-of-treatment claims tied to CFTR-mediated disease in pediatric patients, including specific CFTR gating mutations and age/weight carve-outs.
What does US Patent 10,272,046 claim, and what is the enforceable core?
Featured-snippet answer: The patent protects a unit-dose mini-tablet/granule/pellet composition containing an amorphous solid dispersion of Compound 1 (a defined N-(…)-quinoline-3-carboxamide) at 30–50 wt% with HPMCAS at ~19.5 wt% of the dispersion and SLS at ~0.5 wt% of the dispersion, plus a lactose/mannitol matrix at 1:3 (mannitol:lactose), plus sucralose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate, with the constraint that SLS is not present outside the solid dispersion. It also protects pediatric CFTR-mediated disease treatment using that composition.
Claim-1 composition: what is locked down by the numbers?
Claim 1 is the anchor claim. It is drafted as a closed formulation with both quantitative ranges and compositional constraints.
A. Drug substance identity and physical state
- “Amorphous or substantially amorphous” N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1).
- The solid dispersion contains:
- ~80 wt% Compound 1 (of the dispersion)
- ~19.5 wt% HPMCAS (of the dispersion)
- ~0.5 wt% SLS (of the dispersion)
B. Solid dispersion amount in the final unit-dose
- Solid dispersion is 30–50 wt% of the composition.
This is a first enforceable boundary: a competitor that uses a similar dispersion but shifts the dispersion fraction outside 30–50% misses Claim 1.
C. Filler/binder system and fixed ratio
- Mannitol + lactose total: 30–60 wt% of the composition.
- Ratio: 1:3 mannitol:lactose.
This is a second enforceable boundary: swapping lactose for other disaccharides or shifting mannitol:lactose ratio outside that band breaks Claim 1.
D. Sweetener
E. Disintegrant
- Croscarmellose sodium: 4–8 wt%.
F. Glidant/anti-adherent
- Colloidal silicon dioxide: 0.5–1.5 wt%.
G. Lubricant
- Magnesium stearate: 0.5–1.5 wt%.
H. Crucial placement constraint for SLS
- “Wherein the composition does not comprise SLS outside the solid dispersion.”
This is the most defensible “design-around” stopper in Claim 1. Competitors cannot merely include SLS to help disintegration or compressibility; SLS must be confined to the dispersion fraction and absent from the remaining composition.
Claims 2–12: dosage amount, unit design, and mini-tablet physical characteristics
Drug load range (Claim 2)
- Unit dose contains 1 mg to 100 mg of amorphous Compound 1.
This converts the composition claim into a dosage form boundary.
Specific dose embodiments (Claims 3, 4, 8, 10)
- About 50 mg (Claims 3, 8)
- About 75 mg (Claims 4, 10)
These are likely to map to actual strengths.
Number of mini-tablets (Claims 5, 7, 9)
- Claim 5: 25–40 mini-tablets per unit.
- Claim 7: at 35 wt% dispersion, unit includes ~26 mini-tablets and ~50 mg drug load.
- Claim 9: at 35 wt% dispersion, unit includes ~39 mini-tablets and ~75 mg drug load.
This creates a manufacturing layout constraint: mini-tablet count ties back to total drug mass, tabletting size, and fill strategy.
Mini-tablet geometry and dimension (Claim 6)
- Shape: cylinder-like, oval-like, cone-like, sphere-like, ellipsis-like, polygon-like, or combinations.
- Longest dimension/diameter: about 2 mm.
A competitor can potentially avoid by changing geometry and dimension, but the claim language is broad on shapes while narrow on dimension. At minimum, a 2 mm longest dimension appears as a design target.
Solid dispersion tighter bands (Claims 11–12)
- “Any one of claims 1–5” includes:
- dispersion 30–40 wt% (Claim 11) and
- dispersion about 35 wt% (Claim 12)
Those dependent claims emphasize the preferred embodiments (likely the ones that were actually developed and tested).
How broad is the claim coverage versus obvious variants?
Featured-snippet answer: Coverage is broad on the unit-dose “one or plurality of granules/pellets/mini-tablets” and on mini-tablet shapes, but narrow on the internal makeup of the solid dispersion (Compound 1/HPMCAS/SLS ratios) and on excipient quantitative ranges plus a strict restriction that SLS is absent outside the solid dispersion.
Breadth points (what a generic or alternate formulation might still infringe)
- “Unit dose form comprising one or a plurality of granules, pellets, particles or mini-tablets” means infringement can occur whether the unit contains multiple discrete mini-tablets or other particulate units, as long as the composition matches Claim 1.
- Mini-tablet shapes are enumerated broadly; only the dimension is constrained (2 mm longest dimension).
- The amorphous state language covers “substantially amorphous or amorphous,” reducing the ability to avoid by minor crystallinity differences.
Narrowness points (what likely avoids infringement)
- SLS outside dispersion is prohibited. If a competitor uses SLS as a standalone excipient, Claim 1 is likely missed.
- The dispersion fraction in the final composition is limited to 30–50 wt%.
- The dispersion internal composition is limited to ~80/19.5/0.5 (Compound 1/HPMCAS/SLS). Even if the final composition matches, shifting HPMCAS or SLS in the dispersion may change infringement.
- The mannitol:lactose ratio is fixed at 1:3.
What CFTR-mediated disease and pediatric limitations are enforced by method claims?
Featured-snippet answer: The patent also claims pediatric treatment methods for CFTR-mediated disease using the claimed composition. The independent method claim is broad on CFTR-mediated disease, but dependent claims specify cystic fibrosis (including specific CFTR gating mutations) and include age and weight limitations.
Claim-13: method of treatment anchor
- “Treating or lessening the severity of CFTR mediated disease in a pediatric patient” via administration of the Claim 1 composition.
This ties infringement to patient population and treatment use.
Claim-14: disease list (dependent)
- CFTR-mediated disease is selected from:
- cystic fibrosis
- COPD
- emphysema
- dry-eye disease
- osteoporosis
This expands potential label/application risk beyond CF.
Claim-15–17: cystic fibrosis + gating mutations
- CFTR-mediated disease is cystic fibrosis.
- Patient “possesses a CFTR gating mutation.”
- Mutations enumerated:
- G551D
- G178R
- G551S
- G970R
- G1244E
- S1255P
- G1349D
- S549N
- S549R
- S1251N
This is a key scope modifier. If a competitor targets non-gating CF mutations, method-claim coverage may narrow.
Claims 18–21: age and weight carve-outs
- Age:
- 2 through 5 years (Claim 18)
- 0 through 2 years (Claim 19)
- Weight:
- 14 or more kilograms (Claim 20)
- less than 14 kilograms (Claim 21)
These dependent claims define sub-populations. In litigation, enforcement typically tracks the narrowest applicable dependent claim that the accused use matches.
Claims 22–23: method tied to dispersion amount
- For the method claims, dispersion is further limited:
- 30–40 wt% (Claim 22)
- ~35 wt% (Claim 23)
That links method infringement to a manufacturing specification, not only to indication.
What is the practical claim construction risk for competitors?
Featured-snippet answer: Risk is highest where a competitor uses the same amorphous solid dispersion design with HPMCAS/SLS internal ratios and confines SLS to the dispersion while matching the lactose/mannitol 1:3 ratio and the numeric ranges for all excipients. Risk drops if any of the internal dispersion ratios, SLS placement, dispersion fraction, or lactose/mannitol ratio are materially changed.
Likely infringement “sweet spots”
- Amorphous Compound 1 solid dispersion with HPMCAS and SLS as defined at the dispersion level.
- Final formulation that sets dispersion at ~35 wt%.
- Lactose/mannitol at 1:3 and with sucralose/croscarmellose/cabosil/mag stearate within the ranges.
Likely design-around “attack surfaces”
- Remove SLS from the formulation entirely or use a different surfactant/excipient.
- Use an alternative polymer to HPMCAS within dispersion (or different amounts).
- Adjust dispersion loading outside 30–50 wt%.
- Change lactose:msecondary sugar ratio or mannitol proportion away from 1:3.
- Use a mini-tablet unit where the longest dimension is not about 2 mm (and where the product is not “about” within the same technical range).
How do the dependent claims map to potential product strengths and dosing regimens?
Featured-snippet answer: The patent’s dependent claims appear designed around two strengths (50 mg and 75 mg Compound 1 per unit) and fixed mini-tablet counts corresponding to 35 wt% dispersion.
Strength-to-structure mapping in the claims
| Dependent claim | Dispersion level | Unit drug load | Mini-tablet count | Mini-tablet size |
|---|---:|---:|---:|---|
| Claim 3 / 8 | implied ~35 wt% (in 7/8) | ~50 mg | ~26 (Claim 7) | ~2 mm longest dimension (Claim 6) |
| Claim 4 / 10 | implied ~35 wt% (in 9/10) | ~75 mg | ~39 (Claim 9) | ~2 mm longest dimension (Claim 6) |
| Claim 5 | not specified | 1–100 mg range governed by Claim 2 | 25–40 mini-tablets | 2 mm target (Claim 6) |
| Claim 2 | broad | 1–100 mg | N/A | 2 mm target (Claim 6 if mini-tablets) |
From a landscape perspective, those embodiments look like the commercially relevant configurations that would be targeted for FDA product specs and scale-up.
What does the patent landscape look like around US 10,272,046 in the U.S.?
Featured-snippet answer: Based solely on the information provided (claim text only), a complete U.S. “landscape” cannot be accurately enumerated. This patent’s scope is specific enough that infringement risk analysis would usually be anchored to U.S. Orange Book listings for the relevant dosage form and any related formulation solid-dispersion patents, but those listings are not included here.
Because no bibliographic record (filing date, priority, assignee, or publication numbers), no related family members, and no Orange Book entries or litigation dockets are provided, an accurate cross-patent mapping cannot be produced without inventing data.
Key takeaways
- Core composition claim is tight. Claim 1 requires a defined amorphous solid dispersion internal makeup (~80 wt% Compound 1, ~19.5 wt% HPMCAS, ~0.5 wt% SLS of the dispersion) and places SLS only inside the dispersion (“no SLS outside the solid dispersion”).
- Excipient system is numerically constrained. The formulation locks dispersion loading (30–50 wt%), mannitol:lactose ratio (1:3), and multiple ranges for sucralose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.
- Form factor is partially constrained. It is broad on particle types and tablet shapes but narrows on mini-tablet ~2 mm longest dimension and on mini-tablet count in key embodiments.
- Method-of-use coverage is pediatric CFTR-mediated. The patent covers treatment/lowering severity in pediatric patients, with cystic fibrosis narrowed further by gating mutations and age/weight dependent constraints.
- Design-around strategy should target “SLS placement” and “dispersion internal ratios.” Changing those elements is more likely to break claim 1 than altering only external excipient ranges.
FAQs
- Does Claim 1 cover a formulation where SLS is present as a standalone excipient outside the solid dispersion?
- Can a competitor avoid infringement by changing only the mini-tablet shape while keeping 2 mm longest dimension?
- If a product uses the same polymers but shifts the solid dispersion from 30–50 wt% to 25–29 wt%, does Claim 1 likely fall away?
- Are only cystic fibrosis gating mutations covered by the method claims, or do other CFTR-mediated diseases also qualify?
- What dosage strengths does the patent’s claim set most directly emphasize for infringement risk (50 mg vs 75 mg)?
References
- United States Patent 10,272,046 (claim text provided).
